(1)
Efficacy and Safety of Bevacizumab in Neoadjuvant and Concurrent Chemoradiotherapy for Refractory Cervical Cancer Patients. Biomol Biomed 2024, 24 (6), 1586–1594. https://doi.org/10.17305/bb.2024.10528.